KEYTRUDA pembrolizumab (rch) 100mg/4 mL concentrated injection vial Merck Sharp & Dohme (Australia) Pty Ltd
Product name
KEYTRUDA pembrolizumab (rch) 100mg/4 mL concentrated injection vial
Accepted date
Jul-2024
Active ingredients
pembrolizumab
Proposed indication
For the treatment of unresectable advanced or metastatic malignant pleural mesothelioma.
Application type
C (new indication)
Publication date
Jul-2024